Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 23, 2023 08:00 ET | Source: Eyenovia, Inc.

Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30

NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with...
February 28, 2023 16:05 ET | Source: Eyenovia, Inc.

Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House’s Office of Public Engagement

NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its...
February 15, 2023 09:51 ET | Source: Eyenovia, Inc.

Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals

NEW YORK, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its...
January 12, 2023 08:00 ET | Source: Eyenovia, Inc.

Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops

NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its...
December 20, 2022 08:00 ET | Source: Eyenovia, Inc.

Eyenovia Announces Participation at the 2023 International Consumer Electronics Show

Booth to feature “smart” remote patient monitoring capabilities being developed for future versions of the company’s novel Optejet® drug delivery technology Company to occupy booth 8311 NEW YORK,...
December 13, 2022 08:00 ET | Source: Eyenovia, Inc.

Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation

Agency assigns PDUFA action date of May 8, 2023 MydCombi™, if approved, would be the first product incorporating Eyenovia’s novel Optejet® drug delivery technology Company also announced receipt of...
December 08, 2022 08:00 ET | Source: Eyenovia, Inc.

Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President

NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its...
November 29, 2022 08:00 ET | Source: Eyenovia, Inc.

Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund

NEW YORK, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its...
November 23, 2022 16:05 ET | Source: Eyenovia, Inc.

Eyenovia to Present at Upcoming BTIG Ophthalmology Day

NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its...
November 10, 2022 16:05 ET | Source: Eyenovia, Inc.

Eyenovia Reports Third Quarter 2022 Financial Results and Provides Business Update

Announced positive results from the second Phase 3 study of MicroLine in presbyopia, VISION-2; Company planning to meet with the FDA to gain alignment on regulatory path forward as a drug/device...